Viridian Therapeutics, Inc. VRDN Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$360.59M-17.0% | -$342.6M-26.9% | -$301.97M-17.5% | -$344.06M-50.9% | -$308.32M-41.3% | ||
| $464K-9.4% | $460K-14.8% | $463K-18.3% | $483K-15.6% | $512K-8.9% | ||
| $47.47M+19.6% | $44.3M+5.1% | $41.29M-30.3% | $38.76M-39.5% | $39.68M-38.6% | ||
| -$303.39M-8.5% | -$276.39M-19.0% | -$325.97M-65.5% | -$309.06M-83.7% | -$279.75M-67.1% | ||
| $432K-27.6% | $495K-3.1% | $369K-17.1% | $535K-3.8% | $597K-23.8% | ||
| -$60.36M— | -$37.56M— | $238.94M— | $28.2M— | —— | ||
| $423.89M+46.2% | $426.74M-6.8% | $56.36M-90.9% | $290.52M-25.8% | $289.87M-26.5% | ||
| $60.13M+145% | $112.79M+3,589% | -$30.67M-135% | $9.66M— | $24.57M— | ||
| -$303.82M-8.4% | -$276.89M-18.9% | -$326.34M-65.3% | -$309.6M-83.4% | -$280.35M-66.7% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does Viridian Therapeutics, Inc.'s cash flow data come from?
- Every line is extracted from Viridian Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.